Your browser doesn't support javascript.
loading
Thiotepa-melphalan myeloablative therapy for high-risk neuroblastoma.
Yamazaki, Fumito; Yamasaki, Kai; Kiyotani, Chikako; Hashii, Yoshiko; Shioda, Yoko; Hara, Junichi; Matsumoto, Kimikazu.
Affiliation
  • Yamazaki F; National Center for Child Health and Development, Children's Cancer Center, Tokyo, Japan.
  • Yamasaki K; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Kiyotani C; Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan.
  • Hashii Y; National Center for Child Health and Development, Children's Cancer Center, Tokyo, Japan.
  • Shioda Y; Department of Pediatrics, Osaka University Hospital, Osaka, Japan.
  • Hara J; National Center for Child Health and Development, Children's Cancer Center, Tokyo, Japan.
  • Matsumoto K; Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan.
Pediatr Blood Cancer ; 68(6): e28896, 2021 06.
Article in En | MEDLINE | ID: mdl-33788375
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melphalan / Neuroblastoma Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Infant Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2021 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melphalan / Neuroblastoma Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Infant Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2021 Type: Article Affiliation country: Japan